First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing >/= 50% PD-L1 (ESCKEYP GFPC 05-2018). Corre R, Decroisette C, Auliac JB, Falchero L, et al. Clin Lung Cancer 2025;26:331-337.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Corre R, Decroisette C, Auliac JB, Falchero L, et al. First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing >/= 50% PD-L1 (ESCKEYP GFPC 05-2018). Clin Lung Cancer 2025;26:331-337.
PMID: 40122771